Generative AI biotech partners with cancer center in bid to speed up CAR-T development in solid tumors
One of the biggest startups using generative AI to design protein-based therapies is betting its technology may help crack one of the toughest problems in cell therapy: getting CAR-T cells to target solid tumors.
Generate:Biomedicines announced Wednesday morning that it struck a collaboration with Roswell Park Comprehensive Cancer Center in Buffalo, NY, to co-develop up to three CAR-T cell therapies for ovarian cancer and other solid tumors. The two groups will equally split the cost of designing and developing the treatments and any profits if they prove successful.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.